-0.19  -2%
Previous Close 10.34
Open 10.34
Price To Book 3.57
Market Cap 445,473,502
Shares 43,889,015
Volume 19,515
Short Ratio
Av. Daily Volume 39,916

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 4Q 2019.
Uterine fibroids
Phase 2a Part B interim analysis due 2Q 2019. Timeline missed. Estimate 3Q.
Pre-term labor
Phase 3 data released February 26,2018 - primary endpoint met. Improvement shown in ET D5 subgroup but not in ET D3.
Phase 3 data due 1H 2020.
Uterine fibroids
Phase 2b presented June 25, 2019.
Phase 3 completion or recruitment announced June 4, 2019 with data due 4Q 2019.
Nolasiban (OBE001) - IMPLANT 4
Improving IVF outcomes
Phase 3 trial to be initiated 4Q 2019 or early 2020.
Nolasiban (OBE001) - IMPLANT 3
Phase 3 initiation announced May 9, 2019.
Linzagolix (OBE2109)- EDELWEISS 2
Phase 3 initiation announced May 9, 2019.
Linzagolix (OBE2109) - EDELWEISS 3

Latest News

  1. ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) July 17, 2019 in New York City
  2. ObsEva Ends Recruitment in Second Uterine Fibroids Study
  3. ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 1 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids
  4. ObsEva appoints industry expert as Chief Medical Officer to further advance its Phase 3 clinical programs
  5. Here is What Hedge Funds Think About ObsEva SA (OBSV)
  6. ObsEva SA to Present Nolasiban and Linzagolix Clinical Data at the ESHRE Annual Meeting June 23-26 in Vienna
  7. ObsEva Progressing Toward U.S. Phase 3 Trial for Nolasiban in IVF Following Recent FDA Meeting
  8. Wedbush: 5 Stocks On Our ‘Best Ideas List’
  9. Edited Transcript of OBSV.O earnings conference call or presentation 9-May-19 12:00pm GMT
  10. ObsEva SA Announces Completion of Patient Recruitment in IMPLANT 4 Phase 3 Clinical Trial of Nolasiban for Improving IVF Outcomes
  11. Does The ObsEva SA (NASDAQ:OBSV) Share Price Fall With The Market?
  12. ObsEva SA to Participate in Upcoming Investor Conferences
  13. ObsEva SA (OBSV) Q1 2019 Earnings Call Transcript
  14. Here’s What Hedge Funds Think About ObsEva SA (OBSV)
  15. ObsEva SA (OBSV) Reports Q1 Loss, Lags Revenue Estimates
  16. ObsEva Reports First Quarter 2019 Financial Results
  17. ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and Europe
  18. ObsEva SA Announces that ObsEva’s Shareholders Approved all Board Proposals at its 2019 Annual General Meeting held on May 8, 2019
  19. The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen
  20. ObsEva SA Reports Consistent Long-Term Findings from Phase 2b EDELWEISS trial of Linzagolix for Endometriosis-Associated Pain